

# OHMR Research Ethics and Governance Metrics Program



## Metrics Activity Report for NSW PHOs

Reporting Period: Quarter 3 2022  
01/07/2022 – 30/09/2022

**NSW Office for Health and Medical Research**

## Executive Summary

This report includes strategic and site level performance and compliance metrics that are collected by the Office for Health and Medical Research (OHMR) from NSW Public Health Organisations (PHOs) on studies authorised during the reporting period. The performance of NSW PHOs on health and medical research are reported four times a year, each covering a 3-month period.

## Overall Performance Environment

REGIS is the online platform used to manage ethics and governance applications for all NSW Public Health Organisations. OHMR has undertaken data validation activities with LHD Research Office staff to accurately represent research ethics and governance performance on this platform. These rolling validation activities may result in data reported here to differ from previous reports.

## Update to Metrics Program

As reported previously, OHMR implemented the following changes to the Research Key Performance Indicators (KPIs) for inclusion in the Chief Executives' Services Agreement:

- Change benchmark to/measure/Total Time/rather than time spent with LHD Research Office alone
- Number of Greater than Low Risk projects (GLR) processed within application total time
  - 90 days for ethics, 60 days for governance
  - Threshold changes
    - >75% = Performing
    - 55%-75% = Underperforming
    - <55% = Not performing



## Ethics Review Timelines of Human Research in NSW PHOs

### KPI21-03: Ethics Application Approvals - By the Human Research Ethics Committee (HREC) within 90 calendar days

**NSW State Benchmark:** The benchmark for the 2021/22 financial year onwards is for reviewing human research studies by NSW PHO HRECs within 90 calendar days

#### Definition:

The proportion of Ethics applications (excluding LNR) approved by the HREC within 90 calendar days, approved within the reporting period.

#### Context:

The measure will no longer account for clock stops in accordance with the NHMRC Certification Handbook. Instead, the end-to-end time will be measured. Where a valid application is received, the clock starts on the submission closing date for the HREC meeting at which an application will be reviewed. The clock is stopped when the HREC formally notifies the applicant of the final decision.

#### Desired Outcome:

Ensuring timely processing of ethics approvals for research and clinical trials supports better health outcomes for the people of NSW and maintaining competitiveness through access to the latest treatments from clinical trials.

#### Selection Criteria Summary:

Scope	Human Research Ethics Applications
Frequency	Quarterly
Inclusions	<ul style="list-style-type: none"> <li>Study Type = All</li> <li>Application Type = Greater than low risk</li> <li>Approval Type = Approved/ Approved with conditions within the reporting period</li> </ul>
Exclusions	<ul style="list-style-type: none"> <li>Application Type = Low and negligible risk</li> <li>Approval Type = Not within the reporting period</li> <li>Migrated studies</li> </ul>

#### Total

Total time is defined as the measurement of the total, unadjusted time from the Submission Closing Date of the first meeting the application is assigned to, to when the final decision notification email is sent.

### Summary for Metric 3

Ethics review performance of NSW HRECs according to the **<90-day benchmark** for studies approved during the reporting period (**Quarter 3 2022**) are shown in **Table 1**.

During the reporting period, 220 studies (greater than low risk pathway) were approved by a NSW Health HREC with an average review time (total time) of 75 days. Of these 220 studies, 81 ( 37% ) were classified as clinical trials (**Table 2**).

Further breakdown of clinical trial approvals by sponsor type is provided in **Table 3** (by NSW PHOs) and **Table 4** (by quarter). Historical performance of NSW PHOs against the old and new benchmarks for the review and approval of human research ethics applications is presented in **Table 5**.

**Table 1.** The 90 calendar days benchmark for approval of human research ethics applications (**greater than low risk**) during the reporting period.

NSW PHOs	Ethics Approval (Q3 2022)						
	All greater than low risk applications						
	Total Number of Applications	Total Time 90 Day Benchmark			Total Time Breakdown (calendar days)		Count Request for Information
		Count <90 Day Benchmark	% <90 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Researcher Time	
BLLBRRY	22	19	86%	50	26	24	1.8
CINSW	8	6	75%	198	46	152	2.4
HNELHD	26	25	96%	42	19	23	1.1
ISLHD	3	3	100%	53	45	8	1.0
JHFMHN	6	3	50%	136	71	65	1.0
NBMLHD	4	4	100%	65	46	19	1.0
NNSWLHD	3	1	33%	92	50	41	2.0
NSLHD	12	9	75%	76	45	31	2.4
SCHN	9	7	78%	52	28	24	1.0
SESLHD	15	14	93%	71	32	39	2.1
SLHD-CCD	9	9	100%	64	26	38	1.9
SLHD-RPA	43	43	100%	40	16	24	1.4
SVHN	19	16	84%	64	41	23	1.5
SWSLHD	15	8	53%	125	30	95	2.7
WNSWLHD	4	3	75%	78	45	33	2.5
WSLHD	22	18	82%	143	47	96	1.6
<b>TOTAL</b>	<b>220</b>	<b>188</b>	<b>85%</b>	<b>75</b>	<b>32</b>	<b>44</b>	<b>1.7</b>

**Table 2. The 90 calendar days benchmark for the approval of clinical trials (greater than low risk) during the reporting period.**

NSW PHOs	Ethics Approval (Q3 2022)						
	Clinical Trials						
	Total Number of Applications	Total Time 90 Day Benchmark			Total Time Breakdown (calendar days)		Count Request for Information
		Count <90 Day Benchmark	% <90 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Researcher Time	
BLLBRRY	21	19	90%	47	25	22	1.5
CINSW	0	0	-	-	-	-	-
HNELHD	10	9	90%	51	21	31	1.4
ISLHD	0	0	-	-	-	-	-
NSLHD	3	3	100%	85	43	42	2.7
SCHN	5	4	80%	61	34	27	1.0
SESLHD	3	3	100%	38	19	19	2.3
SLHD-CCD	2	2	100%	72	29	43	2.0
SLHD-RPA	13	13	100%	41	17	24	1.4
SVHN	10	9	90%	59	35	24	1.4
SWSLHD	5	2	40%	96	28	68	3.0
WNSWLHD	1	1	100%	57	31	26	1.0
WSLHD	8	5	63%	270	50	220	1.4
<b>TOTAL</b>	<b>81</b>	<b>70</b>	<b>86%</b>	<b>76</b>	<b>28</b>	<b>48</b>	<b>1.6</b>

**Table 3.** Breakdown of NSW PHO performances in **clinical trial approvals** (greater than low risk) during the reporting period **by sponsor type**

	Collaborative group			Commercial entity			Investigator-initiated		
NSW PHOs	Total # of Applications	Average	Average	Total # of Applications	Average	Average	Total # of Applications	Average	Average
		Research Office Time (days)	Total Time (days)		Research Office Time (days)	Total Time (days)		Research Office Time (days)	Total Time (days)
BLLBRRY	1	8	8	19	25	44	1	46	145
CINSW	0	-	-	0	-	-	0	-	-
HNELHD	1	19	26	2	17	41	7	22	58
ISLHD	0	-	-	0	-	-	0	-	-
NSLHD	0	-	-	0	-	-	3	43	85
SCHN	1	21	51	2	28	51	2	48	77
SESLHD	1	23	37	0	-	-	2	17	38
SLHD-CCD	0	-	-	2	29	72	0	-	-
SLHD-RPA	1	23	61	0	-	-	12	16	39
SVHN	1	51	51	3	30	54	6	35	63
SWSLHD	1	25	109	3	29	72	1	30	157
WNSWLHD	1	31	57	0	-	-	0	-	-
WSLHD	3	49	126	4	49	428	1	56	68
<b>Grand Total</b>	<b>11</b>	<b>32</b>	<b>71</b>	<b>35</b>	<b>28</b>	<b>93</b>	<b>35</b>	<b>27</b>	<b>60</b>

**Table 4.** Quarterly **clinical trial approvals** (greater than low risk) in the last 3 reporting period (between 01/07/2022 and 30/09/2022), **by sponsor type**

	Q1 2022			Q2 2022			Q3 2022		
<b>Sponsor Type</b>	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)
<b>Collaborative Group</b>	2	34	67	8	25	44	11	32	71
<b>Commercial Entity</b>	39	29	58	41	32	70	35	28	93
<b>Investigator Initiated</b>	33	34	66	40	28	65	35	27	60
<b>Total</b>	<b>74</b>	<b>31</b>	<b>62</b>	<b>89</b>	<b>30</b>	<b>65</b>	<b>81</b>	<b>28</b>	<b>76</b>

**Table 5. Historical performance of NSW PHOs against the old and new benchmarks** for the review and approval of human research ethics applications (greater than low risk) in the last 3 reporting period (between 01/10/2022 and 30/09/2022).

NSW PHOs		Q1 2022							Q2 2021							Q3 2022						
		Total Number of Applications	45 Day Benchmark (with clock)			90 Day Benchmark (without clock)			Total Number of Applications	45 Day Benchmark (with clock)			90 Day Benchmark (without clock)			Total Number of Applications	45 Day Benchmark (with clock)			90 Day Benchmark (without clock)		
			Count 45 Day Benchmark	% 45 Day Benchmark	Average Research Office Time (Days)	Count 90 Day Benchmark	% 90 Day Total Time Benchmark	Average Total Time (Days)		Count 45 Day Benchmark	% 45 Day Benchmark	Average Research Office Time (Days)	Count 90 Day Benchmark	% 90 Day Total Time Benchmark	Average Total Time (Days)		Count 45 Day Benchmark	% 45 Day Benchmark	Average Research Office Time (Days)	Count 90 Day Benchmark	% 90 Day Total Time Benchmark	Average Total Time (Days)
BLLBRRY	27	23	85%	27	25	93%	54	16	16	100%	27	14	88%	55	22	20	91%	26	19	86%	50	
CINSW	16	11	69%	40	8	50%	82	13	10	77%	36	12	92%	61	8	4	50%	46	6	75%	198	
HNELHD	22	21	95%	20	19	86%	62	15	15	100%	21	15	100%	49	26	26	100%	19	25	96%	42	
ISLHD	4	1	25%	50	3	75%	80	6	2	33%	58	2	33%	89	3	2	67%	45	3	100%	53	
JHFMHN	3	0	0%	61	2	67%	134	0	0	-	-	0	-	-	6	1	17%	71	3	50%	136	
NBMLHD	7	1	14%	46	7	100%	70	2	1	50%	37	2	100%	57	4	2	50%	46	4	100%	65	
NNSWLHD	2	1	50%	38	2	100%	59	0	0	-	-	0	-	-	3	1	33%	50	1	33%	92	
NSLHD	3	3	100%	28	2	67%	80	14	12	86%	37	10	71%	77	12	5	42%	45	9	75%	76	
SCHN	9	4	44%	45	5	56%	85	19	16	84%	29	17	89%	60	9	8	89%	28	7	78%	52	
SESLHD	10	10	100%	28	10	100%	54	11	8	73%	32	9	82%	56	15	13	87%	32	14	93%	71	
SLHD-CCD	3	2	67%	34	3	100%	74	11	11	100%	22	11	100%	41	9	8	89%	26	9	100%	64	
SLHD-RPA	34	34	100%	20	34	100%	43	43	43	100%	15	43	100%	36	43	43	100%	16	43	100%	40	
SVHN	10	10	100%	30	8	80%	59	27	25	93%	30	24	89%	58	19	13	68%	41	16	84%	64	
SWSLHD	18	12	67%	42	15	83%	66	25	20	80%	38	19	76%	99	15	12	80%	30	8	53%	125	
WNSWLHD	2	1	50%	43	2	100%	43	1	1	100%	4	1	100%	4	4	2	50%	45	3	75%	78	
WSLHD	27	18	67%	41	19	70%	72	20	11	55%	45	17	85%	69	22	9	41%	47	18	82%	143	
TOTAL	197	152	77%	32	164	83%	63	226	191	85%	30	196	87%	60	220	169	77%	32	188	85%	75	





## Site-specific Assessment (SSA) Authorisation Timelines of Human Research Projects in NSW PHOs

### KPI21-04: Research Governance Application Authorisations – SSA Authorisations within 60 calendar days

**NSW State Benchmark:** The benchmark for the 2021/22 financial year onwards for authorisation of SSA applications is 60 calendar days

#### Definition:

The proportion of site-specific assessment (SSA) applications (excluding lower to negligible risk) authorised by the Research Governance Office (RGO) within 60 calendar days, authorised within the reporting period.

#### Context:

The measure will no longer account for clock stops in accordance with the National Health and Medical Research Council Certification. Handbook. Instead, the end-to-end time will be measured. The SSA application received date is the date the RGO or designee receives an SSA application from a researcher regardless of whether it is complete and/or deemed valid. The clock is stopped when the final SSA decision letter is provided to the site principal investigator.

#### Desired Outcome:

Ensuring timely processing of site approvals for research and clinical trials supports better health outcomes for the people of NSW and maintaining competitiveness through access to the latest treatments from clinical trials.

#### Selection Criteria Summary:

##### Scope

Site-specific assessment (SSA) applications

##### Frequency

Quarterly

##### Inclusions

- Study Type = All
- Application Type = Greater than low risk
- Approval Type = “Authorised” or “authorised with conditions” within the reporting period

##### Exclusions

- Application Type = Low and negligible risk
- Migrated studies

#### Total Time:

Total time is the measurement of the total, unadjusted time from the Submission Date to when the final decision notification email is sent granting approval.

#### Summary:

SSA review performance of NSW PHOs according to the **<60-day benchmark** for studies authorised during the reporting period (**Quarter 3 2022**) are shown in **Table 6**. During the reporting period,

**488** studies (greater than low risk pathway) were authorised in NSW PHOs with an average review time (total time) of **40** days.

Of these **488** studies, **237** were classified as clinical trials (**Table 7**).

Further breakdown of clinical trial SSA authorisations by sponsor type is provided in **Table 8** (by NSW PHOs) and **Table 9** (by quarter). Historical performance of NSW PHOs against the old and new benchmarks for the review and authorisation of governance applications is presented in **Table 10**.

**Table 6: The 60 calendar days benchmark for authorisation of governance applications (greater than low risk) during the reporting period.**

NSW PHOs	SSA Approvals (Q3 2022)							
	All greater than low risk applications							
		60 Day Benchmark (without clock)			Total Time Breakdown (calendar days)			
	Total Number of Applications	Count of <60 Day Benchmark	% <60 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Head of Dept Time	Average Chief Exec Time	Average Researcher Time
ASNSW	0	0	-	-	-	-	-	-
Calvary	10	10	100%	10	5	1	1	3
CCLHD	7	7	100%	27	4	14	0	9
FWLHD	2	1	50%	80	13	62	0	5
HNELHD	32	31	97%	27	9	6	1	11
ISLHD	19	18	95%	11	2	1	0	8
JHFMHN	2	2	100%	33	30	4	0	0
MLHD	5	5	100%	28	11	6	3	9
MNCLHD	5	5	100%	30	6	6	13	5
NBMLHD	15	12	80%	54	24	11	6	13
NNSWLHD	7	7	100%	17	9	0	1	8
NSLHD	35	25	71%	57	28	9	0	20
NSWHPH	9	7	78%	57	15	18	1	24
SCHN	36	26	72%	76	8	43	0	24
SESLHD	47	41	87%	35	9	7	0	19
SLHD-CCD	22	22	100%	24	2	4	6	13
SLHD-RPA	70	63	90%	27	6	8	4	9
SNSWLHD	0	0	-	-	-	-	-	-
SVHN	29	18	62%	55	9	8	0	37
SWSLHD	61	46	75%	66	6	22	0	37
WNSWLHD	11	11	100%	16	6	6	0	4
WSLHD	64	57	89%	29	6	6	3	15
<b>TOTAL</b>	<b>488</b>	<b>414</b>	<b>85%</b>	<b>40</b>	<b>9</b>	<b>12</b>	<b>2</b>	<b>18</b>

**Table 7: The 60 calendar days benchmark for the authorisation of clinical trials (greater than low risk) during the reporting period.**

NSW PHOs	SSA Approvals (Q3 2022) Clinical Trials							
	Total Number of Applications	60 Day Benchmark (without clock)			Total Time Breakdown (calendar days)			
		Count of <60 Day Benchmark	% <60 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Head of Dept Time	Average Chief Exec Time	Average Researcher Time
ASNSW	0	0	-	-	-	-	-	-
CALVARY	8	8	100%	10	6	0	1	3
CCLHD	5	5	100%	16	4	6	1	6
FWLHD	0	0	-	-	-	-	-	-
HNELHD	14	13	93%	28	8	9	1	11
ISLHD	8	7	88%	16	3	1	0	12
JHFMHN	0	0	-	-	-	-	-	-
MLHD	2	2	100%	36	15	4	5	13
MNCLHD	3	3	100%	34	3	10	14	7
NBMLHD	6	6	100%	40	16	16	4	4
NNSWLHD	2	2	100%	25	9	1	2	14
NSLHD	24	19	79%	52	25	10	0	17
NSWHPTH	0	0	-	-	-	-	-	-
SCHN	22	16	73%	56	8	21	0	27
SESLHD	17	15	88%	34	9	10	0	14
SLHD-CCD	8	8	100%	32	1	5	11	16
SLHD-RPA	23	18	78%	43	11	10	9	13
SNSWLHD	0	0	-	-	-	-	-	-
SVHN	19	13	68%	41	8	7	0	26
SWSLHD	32	23	72%	75	6	31	0	37
WNSWLHD	4	4	100%	27	7	10	0	10
WSLHD	40	35	88%	28	5	4	2	17
<b>TOTAL</b>	<b>237</b>	<b>197</b>	<b>83%</b>	<b>42</b>	<b>9</b>	<b>12</b>	<b>2</b>	<b>19</b>

**Table 8.** NSW PHO performances in clinical trial authorisations (greater than low risk) during the reporting period, by sponsor type.

	Collaborative group			Commercial entity			Investigator-initiated		
NSW PHOs	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)
CALVARY	2	10	10	3	6	8	3	3	13
CCLHD	3	5	19	1	1	13	1	3	13
FWLHD	-	-	-	-	-	-	-	-	-
HNELHD	1	11	53	4	7	33	9	8	23
ISLHD	2	3	38	3	2	7	3	5	11
JHFMHN	-	-	-	-	-	-	-	-	-
MLHD	0	-	-	0	-	-	2	15	36
MNCLHD	0	-	-	3	3	34	0	-	-
NBMLHD	0	-	-	5	13	40	1	30	37
NNSWLHD	0	-	-	0	-	-	2	9	25
NSLHD	5	17	44	15	29	56	4	17	48
NSWHPTH	-	-	-	-	-	-	-	-	-
SCHN	5	8	68	13	9	53	4	7	52
SESLHD	7	10	48	7	11	27	3	3	16
SLHD-CCD	4	0	28	4	1	35	0	-	-
SLHD-RPA	3	6	35	10	13	50	10	11	39
SNSWLHD	-	-	-	-	-	-	-	-	-
SVHN	3	9	45	10	8	40	6	7	40
SWSLHD	9	6	56	14	6	33	9	8	158
WNSWLHD	1	1	1	1	23	49	2	2	29
WSLHD	4	5	32	25	5	25	11	6	35
<b>Total</b>	<b>49</b>	<b>7</b>	<b>43</b>	<b>118</b>	<b>10</b>	<b>37</b>	<b>70</b>	<b>8</b>	<b>48</b>

**Table 9.** Quarterly clinical trial authorisations (greater than low risk applications) approved during the last 3 reporting period, by sponsor type

	Q1 2022			Q2 2022			Q3 2022		
<b>Sponsor Type</b>	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)
<b>Collaborative Group</b>	35	17	44	47	10	33	49	7	43
<b>Commercial Entity</b>	99	10	35	110	8	35	118	10	37
<b>Investigator Initiated</b>	61	13	68	53	9	43	70	8	48
<b>Total</b>	<b>195</b>	<b>12</b>	<b>47</b>	<b>210</b>	<b>9</b>	<b>36</b>	<b>237</b>	<b>9</b>	<b>42</b>

**Table 10.** Historical performance of NSW PHOs against the old and new benchmarks for the review and authorisation of SSA applications (greater than low risk) for the last 3 reporting periods ( between 01/01/2022 and 30/09/2022).

	Q1 2022							Q2 2022							Q3 2022						
LHD	Number of Applications	15 Day Benchmark (without clock)			60 Day Benchmark (without clock)			Number of Applications	15 Day Benchmark (with clock)			60 Day Benchmark (without clock)			Number of Applications	15 Day Benchmark (with clock)			60 Day Benchmark (without clock)		
		Count of 15 Day Benchmark	% 15 Day Benchmark	Average RO Time (Days)	Count of 60 Day Benchmark	% 60 Day Total Time Benchmark	Average Total Time (Days)		Count of 15 Day Benchmark	% 15 Day Benchmark	Average RO Time (Days)	Count of 60 Day Benchmark	% 60 Day Total Time Benchmark	Average Total Time (Days)		Count of 15 Day Benchmark	% 15 Day Benchmark	Average RO Time (Days)	Count of 60 Day Benchmark	% 60 Day Total Time Benchmark	Average Total Time (Days)
ASNSW	0	0	-	-	0	-	-	1	1	1	0	1	1	56	0	0	-	-	0	-	-
CALVARY	13	9	69%	11	13	100%	19	9	8	89%	5	9	100%	7	10	9	90%	5	10	100%	10
CCLHD	16	15	94%	8	14	88%	35	7	7	100%	2	6	86%	26	7	7	100%	4	7	100%	27
FWLHD	-	-	-	-	-	-	-	1	1	100%	3	1	100%	16	2	1	50%	13	1	50%	80
HNELHD	40	35	88%	8	33	83%	33	33	30	91%	6	32	97%	18	32	29	91%	9	31	97%	27
ISLHD	10	9	90%	7	10	100%	11	22	21	95%	4	20	91%	20	19	19	100%	2	18	95%	11
JHFMHN	2	0	0%	32	2	100%	40	4	1	0.25	20	3	75%	59	2	1	0.5	30	2	100%	33
MLHD	3	3	100%	12	3	100%	27	3	2	67%	11	3	100%	20	5	4	80%	11	5	100%	28
MNCLHD	3	3	100%	7	3	100%	26	8	6	75%	13	7	88%	50	5	5	100%	6	5	100%	30
NBMLHD	18	11	61%	14	12	67%	56	14	13	93%	8	10	71%	57	15	8	53%	24	12	80%	54
NNSWLHD	3	2	67%	9	3	100%	25	5	1	20%	26	5	100%	31	7	5	71%	9	7	100%	17
NSLHD	24	10	42%	19	16	67%	61	25	4	16%	34	14	56%	57	35	11	31%	28	25	71%	57
NSWHPH	5	5	100%	7	3	60%	56	6	5	83%	6	3	50%	95	9	4	44%	15	7	78%	57
SCHN	19	11	58%	18	11	58%	66	27	25	93%	10	18	67%	52	36	31	86%	8	26	72%	76
SESLHD	35	27	77%	10	25	71%	42	39	32	82%	12	32	82%	39	47	38	81%	9	41	87%	35
SLHD-CCD	21	15	71%	9	21	100%	25	22	14	64%	12	22	100%	30	22	22	100%	2	22	100%	24
SLHD-RPA	47	47	100%	2	41	87%	32	47	47	100%	2	41	87%	24	70	60	86%	6	63	90%	27
SNSWLHD	3	3	100%	2	1	33%	74	3	3	1	1	3	100%	10	0	0	-	-	0	-	-
SVHN	29	22	76%	13	18	62%	50	23	21	91%	7	16	70%	53	29	24	83%	9	18	62%	55
SWSLHD	56	35	63%	15	32	57%	73	62	60	97%	7	47	76%	42	61	60	98%	6	46	75%	66
WNSWLHD	8	8	100%	2	7	88%	31	8	7	88%	6	7	88%	23	11	9	82%	6	11	100%	16
WSLHD	63	49	78%	12	53	84%	37	73	68	93%	7	64	88%	36	64	63	98%	6	57	89%	29
<b>Total</b>	<b>418</b>	<b>319</b>	<b>76%</b>	<b>11</b>	<b>321</b>	<b>77%</b>	<b>44</b>	<b>442</b>	<b>377</b>	<b>85%</b>	<b>9</b>	<b>364</b>	<b>82%</b>	<b>37</b>	<b>488</b>	<b>410</b>	<b>84%</b>	<b>9</b>	<b>414</b>	<b>85%</b>	<b>40</b>

A list of NSW PHOs names and abbreviations that review and/or authorise human research studies:

Human Research Ethics Committee/ Research Governance Office Names	Abbreviation used in the tables	Ethics	Site
Ambulance Service of NSW	ASNSW		Yes
Bellberry	BLLBRRY	Yes	
Calvary Mater Hospital Newcastle	CALVARY		Yes
Central Coast LHD	CCLHD		Yes
NSW Population & Health Services Research Ethics Committee	CINSW	Yes	
Greater Western LHD	WNSWLHD	Yes	Yes
Hammond Care	HCARE		Yes
Hunter New England LHD	HNELHD	Yes	Yes
Justice Health & Forensic Mental Health Network	JHFMHN	Yes	Yes
Mid North Coast LHD	MNCLHD		Yes
Murrumbidgee LHD	MLHD		Yes
Northern NSW LHD	NNSWLHD	Yes	Yes
Nepean Blue Mountains LHD	NBMLHD	Yes	Yes
Northern Sydney LHD	NSLHD	Yes	Yes
NSW Health Pathology	NSWHPTH		Yes
Royal Rehabilitation Centre Sydney HREC	RRCS	Yes	
Sydney Children's Hospitals Network	SCHN	Yes	Yes
South Eastern Sydney LHD	SESLHD	Yes	Yes
Sydney LHD (Concord Zone)	SLHD – CCD	Yes	Yes
Sydney LHD (RPAH Zone)	SLHD – RPA	Yes	Yes
Southern NSW LHD	SNSWLHD		Yes
St Vincent's Hospital	SVHN	Yes	Yes
South Western Sydney LHD	SWSLHD	Yes	Yes
Illawarra Shoalhaven LHD (joint committee with University of Wollongong)	ISLHD	Yes	Yes
Western Sydney LHD	WSLHD	Yes	Yes



## For more information

This report has been prepared by the Research Ethics and Governance Unit in Office for Health and Medical Research.

For further enquiries and for the use of this report please contact:

**James Cokayne**

**Principal Policy Officer**

**Research Ethics and Governance Unit**

**Office for Health and Medical Research**

[Tel \(02\) 9391 9920](tel:0293919920) | [james.cokayne@health.nsw.gov.au](mailto:james.cokayne@health.nsw.gov.au)

**Yagiz Aksoy**

**Senior Policy Officer**

**Research Ethics and Governance Unit**

**Office for Health and Medical Research**

[Tel \(02\) 9461 7887](tel:0294617887) | [yagiz.aksoy@health.nsw.gov.au](mailto:yagiz.aksoy@health.nsw.gov.au)

**Jackie Nie**

**Policy Officer and Data Analyst**

**Research Ethics and Governance Unit**

**Office for Health and Medical Research**

[Tel \(02\) 9391 9854](tel:0293919854) | [Jackie.nie@health.nsw.gov.au](mailto:Jackie.nie@health.nsw.gov.au)